This article is more than 5 years old. Information may no longer be current.
TearScience announces 50% price reduction in LipiFlow activators
Click Here to Manage Email Alerts
NEW YORK — LipiFlow single-use activators will soon cost much less.
At OSN New York, Joseph Boorady, president and CEO of TearScience, announced that the company will be lowering the cost of its LipiFlow single-use activators by 50% on Nov. 2.
“As of November 2nd, we will be decreasing the cost of the activators,” Boorady told colleagues in a presentation at Ocular Surgery News’ Disruptive Innovations symposium.
Boorady noted that since he started as CEO 9 months ago, capital has been cut by 40%, “and as of November 2nd, we are dropping the price of the activators by 50%.”
Boorady attributed the ability to drop the price of the activators to the “tremendous volume” of the devices being used.
“We want to thank all of those early adopters for really driving the volume with our manufacturers. We have been able to … develop a second supplier and get the cost down by 50%. We are passing 100% of that on to you,” he said.
The LipiFlow activator is a single-use sterile device, used in the LipiFlow device to treat meibomian gland dysfunction. The LipiFlow system applies a combination of heat and pressure to the inner eyelid to remove meibomian gland obstructions, according to the company website.
“We want to make this treatment accessible for our patients who are suffering with meibomian gland disease,” Boorady said. — by David W. Mullin
Disclosure: Boorady reports he is president and CEO of TearScience.